---
title: "Weekly Recap | Alnylam Pharma +5.84%, five-year data sparks rebound"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305533127.md"
description: "Alnylam Pharma (ALNY) rose 5.84% this week to close at $165.04, beating the S&P 500 by roughly 3.33 percentage points. The move was back-end loaded: the stock opened Monday at $156.13, dipped to $149.18 on Tuesday (10 Nov) to mark a 52-week low, then recovered through the rest of the week. Friday (13 Nov) alone added over 5%, with the weekly range running 12.28%. Average daily volume ran about 110% above its 60-session median, pointing to a rebound backed by heavier turnover."
datetime: "2026-11-14T06:04:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305533127.md)
  - [en](https://longbridge.com/en/news/305533127.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305533127.md)
generator: "portal-rs"
---

# Weekly Recap | Alnylam Pharma +5.84%, five-year data sparks rebound

## The Week

Alnylam Pharma (ALNY) rose 5.84% this week to close at $165.04, beating the S&P 500 by roughly 3.33 percentage points. The move was back-end loaded: the stock opened Monday at $156.13, dipped to $149.18 on Tuesday (10 Nov) to mark a 52-week low, then recovered through the rest of the week. Friday (13 Nov) alone added over 5%, with the weekly range running 12.28%. Average daily volume ran about 110% above its 60-session median, pointing to a rebound backed by heavier turnover.

## Key Events

The week’s main story was five-year HELIOS-B data for AMVUTTRA (vutrisiran) in ATTR-CM. On 9 Nov, Alnylam reported sustained benefit for the drug in patients with transthyretin amyloidosis with cardiomyopathy. The stock then rose 5.4% on 12 Nov, with news coverage placing that move alongside the five-year dataset. A separate read came from partner Regeneron: its CIDEB siRNA cut liver fat by up to 80% in an early trial, extending the platform’s reach beyond Alnylam’s own pipeline.

## Analyst Ratings

Across 30 covering brokers, 14 rate it buy, 7 rate it overweight and 9 rate it hold, with no sell or underweight ratings. The consensus recommendation is buy, and the consensus target sits at $299.96, roughly 81.75% above the current price. Targets range from $180 to $455, a wide spread that reflects differing views on the AMVUTTRA launch trajectory and the value of the siRNA platform. Within biotechnology, the stock ranks 4th out of 514 names on analyst ratings.

## The Week Ahead

The macro calendar is dense: the New York Fed manufacturing index lands on 16 Nov (prior 25.5, forecast 18), followed by retail sales and industrial production on 17 Nov. On the company side, the next clear reporting date is the FY2026 annual results on 11 Feb 2027. Whether the bounce off this week’s 52-week low holds will depend on volume follow-through and how macro data affects growth-biotech valuations.

## In Short

One side of the tension is the five-year HELIOS-B dataset and a mostly constructive analyst stance — over half of the 30 covering brokers rate it buy or overweight, with the consensus target about 82% above spot. The other side is the stock’s recent drawdown from around $272 and a rebound that only just started from the 52-week low. The set-up now hinges on patient uptake and sales execution into the annual report, and on whether macro data keeps pressuring high-valuation biotech.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

- [Is Alnylam Pharmaceuticals (ALNY) Undervalued On Strong New AMVUTTRA Data?](https://longbridge.com/en/news/305576549.md)
- [Alnylam Partner Regeneron's CIDEBsiRNA Cuts Liver Fat by Up to 80% in Early Trial](https://longbridge.com/en/news/305034308.md)
- [Alnylam's Amvuttra shows sustained benefit in five-year ATTR-CM study data](https://longbridge.com/en/news/304880409.md)
- [Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM | ALNY Stock News](https://longbridge.com/en/news/304881250.md)
- [Tech outages are causing people to panic buy. Costco is benefitting](https://longbridge.com/en/news/305992986.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**